The FDA’s framework for AI regulation, while robust for premarket evaluation, would benefit from more specific mechanisms for continuous monitoring of AI performance in diverse real-world settings.
A slew of recalled OTC eye drops during the past 2 years has diminished patient trust, but optometrists are equipped to restore it.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback